Novigenix spins-out AI-Powered Immune Intelligence pionneer
Novigenix SA has spun out Novigenix AI, a Swiss precision medicine company commercializing LITOSeek, an AI-driven platform that analyzes blood RNA for immune-derived insights. The split separates Novigenix's colorectal cancer screening business (Colox, ColoxNGS) and Diagnosuite distribution from the AI-focused unit, which is ISO 13485 certified, claims existing revenue, and is positioned for U.S. and European biopharma and clinical trial deployments. Novigenix AI markets immune intelligence for oncology with planned expansion into autoimmune and neurological indications.
Why it mattersNovigenix AI's spin-out launch enables LITOSeek deployment in U.S./EU clinical trials, accelerating patient stratification.
Entities Mentioned
Novigenix SANovigenix AIDiagnosuite
People Mentioned
startupticker.ch